Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer


In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Related Videos
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Don S. Dizon, MD